Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839990 | 0.76 | KIT (0.40) | RIPK1PARP1 | |
| SCHEMBL3661214 | 0.76 | BRD4 (0.47) | RIPK1MAP4K1 | |
| SCHEMBL1772148 | 0.76 | ABL1 (0.45) | — | |
| Hydrochloric Acid SCHEMBL15825545 | 0.74 | KIT (0.39) | RIPK1 | |
| SCHEMBL13260626 | 0.74 | MAP2K1 (0.38) | RIPK1 | |
| SCHEMBL16592793 | 0.74 | TSHR (0.46) | — | |
| SCHEMBL27800120 | 0.73 | EGFR (0.37) | — | |
| SCHEMBL1772016 | 0.73 | KDM5A (0.33) | MAP4K1 | |
| SCHEMBL1772735 | 0.73 | ABL1 (0.40) | MAP4K1 | |
| SCHEMBL1773112 | 0.72 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217965-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | PLEXXIKON INC. | 2024-07-04 | — | — | US | disclosed |
| US-11739088-B2 | Synthesis of heterocyclic compounds | PLEXXIKON INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210340139-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | PLEXXIKON INC. | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217965-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | CBR3, CBR1, CCNL2 | RIPK1 3962/4885MAP4K1 1204/4885PARP1 725/4885 |
| US-11739088-B2 | Synthesis of heterocyclic compounds | CBR3, CBR1, CCNL2 | RIPK1 3962/4885MAP4K1 1204/4885PARP1 725/4885 |
| US-20210340139-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | CBR3, CBR1, CCNL2 | RIPK1 3962/4885MAP4K1 1204/4885PARP1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.